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Background
Recent studies of the radiobiological properties of prostate cancer cells demonstrate a 
low alpha/beta ratio; this suggests that hypofractionation—the delivery of larger radia-
tion doses in a smaller number of treatment cycles—may offer the best chance of long-
term disease control for localized prostate cancer (Brenner and Hall 1999; Brenner et al. 
1998; Vogelius and Bentzen 2013; Carbrera and Lee 2013; Sanfilippo and Cooper 2014). 
Brachytherapy (BT), the temporary or permanent implantation of small, gamma-emit-
ting radioactive sources directly within cancerous tissue, is a highly effective method for 
delivering extremely hypofractionated radiation to the prostate (Sanfilippo and Cooper 
2014; Yoshioka et al. 2011; Ritter et al. 2011; Tselis et al. 2013). The proximity of the radi-
oactive sources to the cancerous lesions, as well as their placement interstitially within 
the prostate gland, ensures that the radioactive sources move with the organ, thereby 
limiting the impact of organ motion on the accuracy of the treatment compared to 
external beam radiation therapy (EBRT). This phenomenon, along with the rapid dose 
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fall-off beyond the edge of the prostate, enables improved, localized dose escalation 
(Lee 2009). Several clinical studies demonstrate excellent long-term biochemical disease 
control rates across risk groups, for both permanent and temporary brachytherapy, and 
either alone or in combination with EBRT or androgen deprivation therapy (ADT) (Tse-
lis et al. 2013; Ishiyama et al. 2014; Martinez et al. 2010; Morris et al. 2015a, b; Hoskin 
2012). A biochemical control and metastasis-free survival rate at 5 years of 94 and 98 %, 
respectively, was shown by Tselis et al. 2013who evaluated 351 localized prostate can-
cer patients treated with high-dose-rate (HDR) brachytherapy (Tselis et al. 2013). Pre-
liminary results demonstrated by the large multi-institutional ASCENDE-RT trial show 
similar long-term control for BT as a boost treatment with EBRT (Morris et al. 2015a, 
b). In addition to long-term survival benefits, BT also offers significant quality-adjusted 
life-years (QALYs) benefits over both EBRT alone and radical prostatectomy (RP), the 
surgical removal of the prostate (Hayes 2010; Steuten and Retel 2013). As a result of the 
significant benefits of delivering dose-escalated brachytherapy, it has been routinely 
recommended, either alone or in combination with other treatment modalities, for the 
treatment of organ-confined disease by the American Brachytherapy Society (ABS), as 
well as the Groupe Européen de Curithérapie (GEC), and the European Society for Radi-
otherapy and Oncology (ESTRO) (Davis et  al. 2012; Yamada et  al. 2012; Hoskin et  al. 
2013).
Despite the many advantages BT offers, there is growing evidence that increasing radi-
ation doses, without improving dose conformity or targeting accuracy, results in unac-
ceptable patient toxicities (Tselis et al. 2013; Morris et al. 2015a, b; Helou et al. 2014). It 
has been hypothesized that improving the sensitivity and specificity with which radia-
tion is targeted to prostatic lesions through novel imaging and therapeutic modalities 
may remove this upper limit on allowable dose escalation (Helou et  al. 2014). In this 
regard, the rapidly expanding fields of multiparametric magnetic resonance imaging 
(mpMRI) and targeted gold nanoparticles (GNPs) are two of the latest methods that 
hold the most promise for enabling safe dose escalation (Wallace et al. 2013; Ghai and 
Haider 2015).
Multiparametric MRI has recently emerged as the imaging modality of choice for 
detection of localized prostate cancer (supplementing the histopathological information 
provided by ultrasound-guided biopsies) and has become part of the standard of care for 
the diagnosis, localization, and staging of prostate cancer, largely due to its superior soft 
tissue contrast and supplementary functional information (Ghai and Haider 2015; Law-
rentscuk and Fleshner 2009; Panebianco et al. 2015; Scheenen et al. 2015; Weinreb et al. 
2016). The addition of multiple functional imaging sequences to the anatomical informa-
tion provided by T2-weighted (T2W) static MR images—including diffusion-weighted 
imaging (DWI), dynamic contrast-enhanced imaging (DCEI), and magnetic resonance 
spectroscopic imaging (MRSI)—produce a wealth of additional information to aid in 
the delineation of active disease (Panebianco et al. 2015; Maneti et al. 2014; Verma et al. 
2012; DiBiase et  al. 2002). More recently, mpMRI has garnered attention in prostate 
brachytherapy treatment planning, for improving both prostate gland and intraprostatic 
lesion localization (Gomez-Iturriaga et al. 2016; Marks et al. 2013; Kaplan et al. 2010; Wu 
et al. 2014; Menard et al. 2004). The advantages provided by co-registering mpMRI with 
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intra-operative transrectal ultrasound (TRUS) within the prostate BT workflow could 
significantly reduce the current limitations imposed on dose escalation; this review will 
examine mpMRI with relation to both its diagnostic and target localization potential for 
BT (Gomez-Iturriaga et al. 2016). Additionally, the development of intra-operative MRI-
only workflows for BT will be examined.
The enhancement of the therapeutic ratio for prostate brachytherapy may also be 
achieved through the use of radiosensitizers to selectively improve radiation dose deliv-
ery to cancerous tissue. Targeted gold nanoparticles (GNPs), due to their physical, 
radiation, and pharmacokinetic properties, are well suited to BT applications with the 
potential to boost local radiation doses to levels unimaginable with EBRT or conven-
tional BT alone (Ngawa et al. 2013; Lechtman et al. 2013; Arnida and Ghandehari 2010; 
Babaei and Ganjalikhani 2014). The addition of radiosensitizers to the BT workflow, in 
combination with the high spatial resolution of MRI, could significantly improve dose 
escalation while further sparing patients the associated increase in toxicities. The cur-
rently available clinical studies and future potential of these novel nanomolecular agents 
will be examined in a BT framework.
By synergistically combining the improved image guidance of mpMRI, and the selec-
tive targeting provided by nanomolecular radiosensitizers, new treatment paradigms 
within the BT workspace can also be realized. Single-treatment BT with biological 
doses beyond what is currently achievable, a greater focus on targeting and treatment 
of intraprostatic lesions or single dominant intraprostatic lesions (DILs), and improve-
ments in focal and salvage therapy are all potential new areas that may see a rapid 
improvement with adoption of new dose-escalation methods. Many of these novel direc-
tions within the BT space will be covered in this review.
The overall goal of this review is to evaluate the current landscape of dose-escalated 
prostate brachytherapy in its present form and examine ways in which mpMRI guidance 
and nanoparticle radiosensitization can selectively improve dose escalation in the future. 
The constantly changing research and clinical landscape of targeted therapy for prostate 
cancer makes it difficult to perform an exhaustive review on this rapidly evolving field; 
this review represents only an instance of the literature at the time of publication.
Clinical overview of prostate brachytherapy
The two most common methodologies for delivering hypofractionated radiation for 
localized prostate cancer are low-dose-rate (LDR) and high-dose-rate (HDR) BT. LDR, 
or permanent implant BT, involves the permanent placement of 80–100 radioactive 
substances within the interstitial space of the prostate gland. High-dose-rate (HDR) BT, 
by comparison, involves the temporary implantation of hollow catheters into the pros-
tate through which a highly radioactive source is remotely passed for a short period of 
time; the transit time of the source within the catheters determines the magnitude of the 
delivered dose. Both workflows generally follow a similar planning framework as rec-
ommended by both ABS and GEC-ESTRO guidelines (Davis et al. 2012; Yamada et al. 
2012; Hoskin et al. 2013). The components of a typical BT patient pathway are as follows: 
(1) diagnosis of localized prostate cancer, (2) pre-operative or intra-operative treatment 
planning and treatment delivery, (3) post-implant quality assurance.
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Diagnosis using MRI
Traditionally, definitive diagnosis of localized prostate cancer relied on the TRUS-guided 
sextant biopsy for identification of cancerous tissue; this approach alone was found to 
leave up to 15 % of cancers undetected and was prone to sampling error (Norberg et al. 
1997). The information from TRUS biopsy is now routinely correlated with imaging 
information provided by multiparametric MRI (mpMRI); this offers a clearer representa-
tion of disease foci and extraprostatic disease extension as well as improved biopsy sam-
pling and characterization as part of staging (Lawrentscuk and Fleshner 2009; Kaplan 
et al. 2002; Cirillo et al. 2008; Pullini et al. 2016). In 2012, the prostate imaging–reporting 
and data system (PI-RADS v.1, updated in 2015/2016) was developed to standardize the 
approach to diagnosis and reporting of mpMRI for prostate cancer (Weinreb et al. 2016); 
several recommendations were made. Diagnosis of prostate cancer should be performed 
using T2-weighted fast spin echo (T2W-FSE) sequences on a 1.5–3T MRI scanner, the 
latter being preferred due to its higher signal-to-noise ratio, along with inclusion of 
functional DCEI, DWI, and potentially MRSI sequences. A high degree of visibility of 
the prostate peripheral zones, along with urethral and rectal structures, seminal vesicles, 
and prostatic capsule (extra- and intracapsular disease) is typically required. Each imag-
ing sequence of the mpMRI acquisition contributes supplementary information that 
facilitates diagnosis and/or staging of localized disease; the PI-RADS reporting system 
further standardizes this approach according to the respective imaging sequence.
T2W-FSE images (see Table  1 for recommended PI-RADS parameters) are typically 
used to discriminate between zonal anatomies of the prostate and discern normal tis-
sue from various abnormalities; however, a number of benign conditions may mimic the 
T2W appearance of prostate cancer including benign prostatic hyperplasia (BPH) or 
prostatitis (Kitajima et al. 2010). Intraprostatic cancerous tissue conversely may also be 
difficult to detect on this imaging alone; Fig. 1 shows a typical example of a multiplanar 
T2W-FSE image of the prostate and surrounding anatomy. The limitations of purely ana-
tomic imaging necessitate the supplementary use of functional imaging sequences.
DWI, a functional method of measuring random water molecule diffusion rates within 
tissue, is typically used to supplement T2W-FSE acquisitions. Prostate cancers pre-
sent with restricted diffusion rates relative to the surrounding normal prostatic tissue, 
Table 1 PI-RADS recommendations for mpMRI sequence parameters




Slice (mm) FOV (cm) In-plane 
dimensions 
(mm)
TR/TE (msec) Additional Contrast
T2W 3 12–20 ≤0.7 × ≤0.4 Not specified – –





DCEI 3 Entire pros-
tate + SV





rate = 2–3 cc/
sec
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a phenomenon that is represented through apparent diffusion coefficient (ADC) maps 
computed at each image voxel (Weinreb et al. 2016; Kim et al. 2010). B values—an indi-
cator of the rate of diffusion that is captured by the image dataset—have recommended 
ranges between 0 and 1000 s/mm2; larger b values are used to detect slower diffusion 
rates of water molecules (Kim et al. 2010). The inclusion of DWI sequences with T2W 
imaging improves detection of prostate cancer, particularly in the peripheral zone 
tumors (Haider et al. 2007). Figure 2 shows a typical DWI axial sequence of the prostate.
DCEI obtained by acquiring T1W image sequences during administration of an intra-
venous gadolinium-based contrast agent (GBCA), is used to further supplement the 
information obtained from both T2W and DWI sequences. DCEI takes advantage of 
cancer angiogenesis, a process that increases vascular density and permeability within 
tumors, to visualize prostatic regions of increased uptake of the GBCA (Verma et  al. 
2012; Singanamalli et al. 2016). Figure 3 shows the differential uptake of GBCA within 
Fig. 1 Multiplanar T2-weighted fast-spin echo (T2W-FSE) images (axial, coronal, and sagittal midplanes) of a 
patient with localized prostate cancer treated with EBRT (45 Gy/25), followed by an HDR BT boost (15 Gy/1). 
The prostate (purple) and dominant intraprostatic lesion (light blue) are not readily visible without supplemen-
tary functional imaging
Fig. 2 Diffusion-weighted imaging (DWI) of an axial midgland plane with high b value ADC map. Areas of 
higher water diffusion rates appear brighter on T2 imaging. Significant cancers may present with restricted 
diffusion rates and are seen as areas of hypointense signal on the ADC map (arrow). The focal lesion is con-
toured for clarity
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areas of active tumor (the DIL), over a set of sequential axial frames. The addition of 
DCEI to the mpMRI sequence has demonstrated improvements in sensitivity and lesion 
detection accuracy (Kitajima et al. 2010; Alonzo et al. 2016).
Magnetic resonance spectroscopic imaging (MRSI), while not as widely adopted as 
DWI or DCEI, is gaining interest as a valuable technique for non-invasively determining 
the biochemical concentrations of biomarkers associated with prostate cancer (Kurhane-
wicz et al. 2002; Picket et al. 2004; Pouliot et al. 2004). MRSI may be more specific in dif-
ferentiating benign conditions from actively metabolic prostate cancer and may provide 
metabolic information associated with tumor progression (Kobus et  al. 2014). In  vivo 
prostate MRSI utilizes the relative or absolute concentrations of the metabolites such 
as choline, polyamines, creatine and citrate, as cancer specific biomarkers, with 98  % 
of cancers demonstrating an elevated (choline + creatine)/citrate ratio greater than the 
ratio for normal tissue (Fig. 4) (Westphalen et al. 2008; Scheenen et al. 2015). Addition 
of the functional information provided by MRSI could potentially improve diagnosis, 
staging, and disease localization for BT. The diagnostic value of combined magnetic res-
onance imaging and spectroscopic techniques has encouraged radiologists and oncolo-
gists to include it increasingly for clinical use.
Pre- and intra-operative image guidance and treatment planning
Once diagnosis and staging of prostate cancer have been completed (and BT is selected 
as a treatment option), the identification of critical target and normal tissue structures 
is made. During this phase, the target, typically the entire prostate gland and/or focal 
lesions, and organs at risk (OARs) are identified for treatment planning (Thomadsen 
et al. 2012; Yu et al. 1999). Historically, CT, TRUS, and more recently mpMRI, have been 
used to identify critical structures (Nath et al. 2009; Metcalfe et al. 2013; Rischke et al. 
2013). Clinical use of CT or TRUS has traditionally been the mainstay of pre-treatment 
imaging for target identification, but recent improvements in the availability of diagnos-
tic MRI scanners have improved access significantly to mpMRI for this purpose (Davis 
et al. 2012; Yamada et al. 2012; Nag et al. 2000; Mayer et al. 2016). Several studies have 
pointed to the subjectivity of contouring on conventional imaging modalities. Better 
Fig. 3 Axial midgland sequence showing dynamic contrast-enhanced imaging (DCEI) acquired using T1W-FSE 
sequences over a 1 min period. Gadolinium-based contrast agent (GBCA) is administered intravenously at an 
injection rate of 2–3 cc per second; lesion enhancement may appear as early as 10 s following injection. Enhance-
ment of the DIL is shown in frames 4 through 7 (arrows), followed by a washout phase where the signal dissipates
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imaging methods are being heralded as a means to provide objectivity to this aspect of 
the planning process (Rischke et al. 2013; Steenbergen et al. 2015; Fiorino et al. 1998).
Pre‑operative guidance prior to MRI
CT-guided BT planning represents one of the earliest attempts to use volumetric imag-
ing to accurately identify targets and OARs, as well as plan radioactive source posi-
tions, with good outcomes; Koutrouvelis et al. (2000) reported prostate-specific antigen 
(PSA)  <2  ng/mL in 90  % of patients (n  =  301) at median 26  month follow-up after 
being treated with permanent implant CT-guided BT (Koutrouvelis et al. 2000). Intra-
operative TRUS-guided BT is rapidly growing in adoption largely due to its lower cost, 
widespread availability, and real-time guidance, and has allowed implant guidance dur-
ing the BT procedure in addition to target localization. Stone et al. (2007), pioneers of 
the TRUS-guided permanent implant approach, reported excellent long-term toxic-
ity outcomes of 325 patients (Stone and Stock 2007; Crook et al. 2011). TRUS-guided 
BT is now the recommended standard of care for prostate BT by both ABS and GEC-
ESTRO guidelines for both LDR and HDR implants (Davis et  al. 2012; Yamada et  al. 
2012; Hoskin et al. 2013). Despite these many advantages, significant TRUS artifact still 
make identification of the target and OARs highly subjective (Fig. 5) (Xue et  al. 2006; 
Solhjem 2004). Further identification of DILs for dose escalation is simply not feasible 
using TRUS guidance alone, and a workflow incorporating mpMRI fusion with TRUS 
imaging is commonly required.
Pre‑operative MRI for treatment planning
MRI, in addition to its diagnostic capability, has been recognized as the ideal imaging 
modality for soft tissue prostate delineation, as well as for discrimination of nearby nor-
mal tissues (Dinh et al. 2016). Using the information obtained from mpMRI radiation, 
oncologists can identify the prostate, focal lesions, and nearby healthy tissues (urethra 
and rectum, commonly) with greater confidence than using TRUS or CT imaging.
However, since the information from mpMRI is typically only available in a pre-oper-
ative setting, an additional imaging modality must be co-registered to obtain contours 
of the target and OARs during the planning stage. Following an initial pre-treatment 
mpMRI the dataset is co-registered with live intra-operative TRUS, a technique adapted 
from advances in TRUS-guided biopsies (Kaplan et al. 2002; Marks et al. 2013). Deline-
ated contours from the mpMRI are then propagated onto the live TRUS images; this 
approach has allowed improved targeting of the prostate, and even potentially DILs, 
without altering the intra-operative imaging modality (DiBiase et al. 2002; Marks et al. 
2013; Crook et al. 2014). Unilateral focal disease has been treated using DCE imaging 
to contour the DIL with the intent of focal dose escalation. Images from the mpMRI 
were transposed onto the intra-operative TRUS. An average of 20–30 % dose escalation 
to the DIL was feasible using this approach (Crook et al. 2014). More recently, Gomez-
Iturriaga et al. (2016) were able to treat 15 patients with a single MR-TRUS-guided HDR 
boost of 15 Gy; the DIL was treated to 18.75 Gy. At a median follow-up of 18 months, 
none of the patients developed grade ≥3 urinary toxicity (Gomez-Iturriaga et al. 2016). 
Although registration errors may occur due to the imperfect correlation of MRI to live 
TRUS imaging, many commercially available deformable registration algorithms have 
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been developed to improve this process and are a growing area of interest (Sparks et al. 
2013). Target and OAR identification continue to pose a challenge for mpMRI-fused BT 
workflows; as a result, the use of intra-operative MRI guidance for BT has garnered sig-
nificant interest in an attempt to alleviate this problem.
Intra‑operative guidance prior to MRI
Current GEC-ESTRO and ABS guidelines for prostate brachytherapy recommend intra-
operative TRUS imaging for visualization of the prostatic capsule, nearby anatomy, and 
implant guidance. Interpretation of TRUS images is highly subjective, leading to diffi-
culties in target, OAR, and source identification during implantation. Figure 5 outlines 
some of the difficulties in identification of catheter trajectories for an HDR prostate BT 
procedure. For HDR BT, once catheter identification has been completed, an optimiza-
tion algorithm is used to determine the optimal dwell times of the radioactive source 
within each catheter with the goal of maximizing the radiation dose to the target(s) while 
minimizing the dose to normal tissues (Fig. 6). A similar process in LDR BT is used to 
determine the configuration of implanted sources within the prostate gland.
Intra‑operative guidance using MRI
The use of intra-operative MRI guidance for prostate brachytherapy arose from earlier 
iterations with interventional TRUS biopsies performed in both open and closed-bore MRI 







































Fig. 4 Magnetic resonance spectroscopic imaging (MRSI) spectra obtained using a conformal voxel 
approach for areas of normal tissue (green voxel), and suspected abnormality (red voxel) and for short 
(TE = 40 ms), and long (TE = 130 ms) echo times. A spectral-spatial RF pulse sequence was used. In a normal 
voxels are displayed demonstrating the appearance of short TE metabolites (i.e., sI—scyllo-inositol) not 
evident at longer echo times. Similarly, in b there is a decrease in relative concentration of citrate to choline 
over voxels with suspected cancer
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brachytherapy, this approach enabled the monitoring of implanted sources and/or needles 
with respect to the soft tissue boundaries of the prostate and normal tissues. These work-
flows typically mimic current intra-operative BT workflows using TRUS guidance. Prostate 
or DIL identification is done by a radiologist in the MRI interventional suite with the patient 
anesthetized in the scanner bore. Intra-operative approaches to MRI-guided BT involv-
ing low-field (0.2–0.5 T) (Cormack et al. 2000; Ares et al. 2009) and high-field closed-bore 
(1.5–3 T) (Menard et al. 2004; Susil et al. 2004) have been evaluated clinically with encour-
aging early results. Low-field, open-bore systems offer improved interventional access to 
the patient, but at the cost of decreased imaging quality due to the lower field strength; 
additionally, the low field strength significantly limits application of DCE imaging and other 
functional techniques. Higher field strength, closed-bore magnets, although creating chal-
lenges for interventional approaches due to the limited access to the patient, offers superior 
image quality and are more readily available in clinical settings (as 1.5 or 3 T units).
The intra-operative workflow outlined by Menard et  al. (2004) is an excellent example 
of an MRI-dedicated HDR workflow using a closed-bore, high-field strength (1.5 T) MRI 
(Menard et  al. 2004). Patients were placed in the left lateral decubitus position into the 
scanner bore and anesthetized using general anesthesia. An endorectal coil was inserted to 
improve visualization of the pelvic anatomy and scout MRI images were obtained to localize 
the treatment site. Catheters (with metallic, MR-safe obturators) were implanted by remov-
ing the scanner table from the scanner isocenter, inserting the catheter, advancing the table 
back to the isocenter, and then re-acquiring FSE sequences to evaluate the catheter posi-
tions (on both axial and sagittal planes). Early clinical results have been promising; however, 
the limitations of the closed-bore procedure increase the procedure time significantly over 
the current standard TRUS-guided techniques (Menard et al. 2004; Ares et al. 2009).
Post-implant quality assurance
Typically, post-implant dosimetry is performed 1 month after an LDR BT implant using 
CT guidance (Fig.  7); the position of the implanted sources are identified, along with 
normal tissues and target volumes, and the isodose distribution is recomputed to evalu-
ate the quality of the delivered treatment (Potters et al. 2001). Post-operative dosimetry 
metrics have been poorly correlated with intra-operative dosimetry; a study by Acher 
et al. (2010) showed that this was largely due to the subjective nature of the contoured 
Fig. 5 TRUS axial, coronal, and sagittal midgland planes for a patient treated with TRUS-guided HDR BT. The 
live TRUS images were co-registered with the contours obtained from mpMRI to yield the prostate (red) and 
DIL (light blue) contours. The difficulty in identifying distal catheters compared to proximal catheters is also 
apparent (arrows)
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prostate volume on CT (Merrick et al. 1999; Acher et al. 2010). MRI-based post-implant 
dosimetry has been proposed to offer improved discrimination between the prostate and 
OARs; however, signal voids around the metallic casings of brachytherapy sources pose a 
challenge for accurate source localization. Thomas et al. (2009) demonstrated that signal 
voids surrounding brachytherapy sources exist for increasing field strengths (3–4.5 mm 
separation for 1.5 T, and 4.5–6 mm for 3 T), which affect the accuracy with which the 
sources are localized; a proton density-weighted FSE sequence was used to limit this 
effect with good results (Thomas et al. 2009). Various studies demonstrated techniques 
to minimize these artifacts; Kuo et  al. (2010) examined an in-phantom method using 
inversion recovery with ON-resonant suppression (IRON) to generate positive contrast 
in areas of high magnetic susceptibility artifact (Kuo et al. 2010). Similarly, positive con-
trast agents such as cobalt dichloride-N-acetyl-cysteine (C4) have been used as encapsu-
lated markers and show promise at a number of different parameters and field strengths, 
without altering the dosimetry of the delivered therapy, and showing minimal patient 
toxicities (Lim et al. 2014; Frank et al. 2008).
The future of targeted prostate brachytherapy
The advent of targeted imaging and treatment techniques has spawned interest in novel 
brachytherapy planning methodologies. The use of mpMRI for improved prostate and 
DIL localization may shift the focus of treatment to preferentially target focal lesions 
with higher radiation doses, while reducing doses to surrounding normal tissues. In 
addition to the improved localization offered by mpMRI, novel radiosensitizing nano-
particles have recently gained popularity as a method to selectively boost the dose of 
radiation to focal lesions beyond conventional means while maintaining normal tissue 
toxicities at current levels.
Fig. 6 Typical HDR prostate BT treatment plan showing axial midgland plane for a patient treated with 19 Gy. 
Twelve catheters (hyperechoic regions) were implanted and dwell times optimized using Oncentra Prostate 
(Elekta AB, Stockholm, Sweden). The organ contours are the prostate (red), urethra (light blue), focal lesion 
(light teal), and rectum (dark brown). The isodose lines are represented as a percentage of the prescription 
dose (arrows)
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Focal and salvage therapy using MRI guidance
Traditionally, the use of CT and TRUS guidance for prostate BT planning was limited to 
treating the entire gland, largely due to the inability to resolve the multifocal nature of 
intraprostatic disease with confidence. The significant improvement in the ability to dif-
ferentiate individual focal lesions using mpMRI enables targeted dose escalation, while 
decreasing the whole-gland dose, thereby significantly reducing the dose to the OARs 
(Muller et al. 2014; Crehange et al. 2014).
Studies evaluating focal boosting to both single and multifocal DILs using both LDR 
and HDR have emerged recently. Ahmed et al. (2012) showed excellent 12 month out-
comes and urinary toxicity following LDR BT focal boost (Ahmed et al. 2012). Banerjee 
et al. (2015) and Gomez-Iturriaga et al. (2016) demonstrated similar results with HDR 
BT showing significant escalation of DIL doses without an expected increase in urinary 
toxicities (Gomez-Iturriaga et  al. 2016; Banerjee et  al. 2015). This approach has also 
shown promise in focal salvage therapy, using both LDR and HDR, in reduction of uri-
nary toxicities while maintaining excellent outcomes comparable to whole-gland salvage 
treatment (Hsu et al. 2013; Duijzentkunst et al. 2016).
These promising hypothesis-generating studies require robust long-term control and 
toxicity data, but they do indicate that focal boosting (and focal salvage therapy) using 
mpMRI-guided HDR and LDR is a feasible method for dose escalation while minimizing 
OAR toxicities.
There exist ample opportunities for multimodality fusion of mpMRI as well as intra-
operative MRI for focal dose escalation. Significant technological hurdles to the imple-
mentation of intra-operative MRI-guided BT make it more likely that multimodality 
fusion will be readily adopted as a means to deliver focal or whole-gland BT. For centers 
that have the ability to implement intra-operative guidance for BT, it is likely that closed-
bore, high-strength MRIs will see increased uptake due to their wider availability and 
ability to deliver high-quality anatomical and functional imaging.
Fig. 7 Post-implant dosimetric quality assurance (QA) for a typical LDR BT treatment plan 1 month following 
implantation. Imaging the prostate (red) and rectum (blue) interface can be challenging on CT-guided post-
implant QA. Isodose lines are shown as a percentage of the prescription dose (145 Gy). Sources are identified 
as green circles with upward-directed and downward-directed triangles representing out-of-plan sources. Treat-
ment planning system is VariSeed 8.0 (Varian Inc. Palo Alto, CA, USA)
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Radiosensitization using gold nanoparticles
Another promising new technique for improving local dose escalation, potentially act-
ing synergistically with the improved image guidance afforded by mpMRI, is the use 
of gold nanoparticles (GNP) for selective radiosensitization of tumors (Jain et al. 2012; 
Babaei and Ganjalikhani 2014). The main mechanism of action of these nanoparticles is 
the production of photo- and Auger electrons by the photoelectric effect after bombard-
ment with photons (Spiers 1949; Castillo et al. 1988). The short range of these electrons 
requires that cytosolic uptake of GNPs occurs to create DNA single- and double-strand 
breaks (Zheng et al. 2008). The selective dose enhancement factor (DEF)—the increased 
effect of local radiation dose deposition due to the GNPs—has been observed with high 
GNP concentrations in conjunction with keV photon energies as outlined by Zhang et al. 
2008, Rahman et al. (2009) and Roeske et al. (2007). The introduction of GNP-mediated 
radiosensitization both for LDR and HDR brachytherapy, which emit gamma photon 
energies in the ideal range for maximizing DEF, holds significant promise.
Due to the long half-life of most LDR brachytherapy sources, GNPs introduced into 
cancerous cells must remain within the cell cytosol for extended periods of time to suf-
ficiently provide a dose-enhancement effect. Shorter periods of GNP uptake by prostate 
cancer cells may be suitable for HDR delivery, due to the rapid radiation delivery (in the 
order of 10–30 min), and it therefore may serve as an easier pathway to GNP integra-
tion within the BT framework. Further development and customization of GNPs to spe-
cifically tailor them for use in prostate BT should focus on the route of administration, 
pharmacokinetics, and cellular uptake.
The geometric and functional parameters of GNPs play an important role in their 
uptake as outlined in Albanese et al. (2012), Perrault et al. (2009) and Favi et al. (2015). 
Naïve GNPs without additional ligands preferentially accumulate at sites of porous and 
leaky tumor vasculature (Jain et al. 2012). The addition of ligands such as polyethylene 
glycol (PEG) allow improved non-specific uptake by receptor-mediated endocytosis 
(RME) within tumors, as well as improved transit times in systemic circulation (Zhang 
et al. 2008; Kumar et al. 2013; Lechtman et al. 2013; Chithrani et al. 2006). Further func-
tionalization by addition of tumor-specific ligands may enable GNPs to further target 
prostate cancer with increased specificity. Of importance in uptake and clearance is 
GNP size: smaller GNPs tend to have rapid circulations when administered intrave-
nously and are quickly cleared by the renal system but more rapidly permeate tumor 
vasculature, while excessively large particles may have significantly increased uptake by 
the Reticuloendothelial System (RES), a process which decreases selective DEF (Arnida 
and Ghandehari 2010; Maeda et al. 2001).
In contrast to systemic administration, the intra-operative nature of BT procedures 
may enable interstitial injection of GNPs directly within focal lesions outlined on 
mpMRI. In this proposed workflow, the pre-treatment mpMRI-TRUS—or intra-opera-
tive MRI—could be used to localize focal lesions and the high spatial resolution of MRI 
could be used to guide deposition of high concentrations of GNPs directly within these 
cancerous foci during the BT procedure. This approach may significantly reduce the 
need for larger GNP sizes with their increased residence time, thereby taking advantage 
of the benefits of small GNP sizes. Evidence suggests that a medium range (6–50 nm) 
PEGylated, spherical GNP, administered interstitially, could allow sufficient tumor 
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uptake and retention over the course of LDR BT to offer a significant dose-enhancement 
effect (Chithrani et al. 2006). For HDR BT, a smaller size (<6 nm) PEGylated, spherical 
GNP may be more suitable, allowing for a residence time and dispersion that correlated 
with the procedure duration, thereby producing the required dose enhancement with 
fewer potential side effects. GNPs could be administered during the procedure and rap-
idly cleared from circulation afterward. Commercially available GNPs specifically opti-
mized for radiation therapy are also being developed to have longer circulation, small 
sizes (2–3  nm), higher tumor uptake, and improved clearance (Kumar et  al. 2013). It 
remains to be seen if the pharmacokinetics of these commercially available GNPs is sim-
ilar when administered locally within the prostate gland.
Conjugation of gadolinium with GNPs (Gd-GNP) could also allow for visualization on 
intra-operative MRI and offer a means of calculating the biological effective dose from 
the additive effects of GNPs during HDR BT (Harisinghani et al. 2003; Debouttiere et al. 
2006; Le Duc et al. 2014). Vartholomeos et al. 2011 also examined the use of MRI-com-
patible nanoparticles to act as drug-delivery nanorobots under MRI-guided steering; 
similar methodologies may be applied to both track and steer injected GNPs to tumor 
vasculature within the prostate gland during BT (Vartholomeos et al. 2011).
There remain significant challenges with local deposition of high GNP concentrations 
within the prostate gland largely relating to their diffusion and uptake within the tumor 
vasculature. The assumption of homogenous GNP distribution with local administra-
tion may not be accurate, especially with local administration; problems with inconsist-
ent tumor vasculature (particularly in hypoxic tumor regions) may cause poor uptake 
or heterogeneous GNP distribution even within small focal lesions. It is prudent to 
assume that focal lesions neighboring normal tissues, such as the urethra, may be at risk 
of excessive local hot spots with uneven GNP distribution and therefore further explora-
tion is needed. Additionally, although systemic toxicities of GNP administration have 
been noted as minimal in some studies (Alkilany and Murphy 2010; Fratoddi et al. 2014), 
the examination of toxicities from localized injection of high GNP concentrations within 
the prostate requires further study if they are to be used in BT.
Conclusions
Although long-term biochemical control and toxicity results of mpMRI-guided BT are 
forthcoming, it is expected that this method will continue to drive high-precision dose 
escalation for localized prostate cancer in the near future. The ability to deliver large local-
ized doses to focal lesions within the prostate gland has profound implications for BT as 
first-line therapy as well as salvage therapy. Inclusion of GNPs to improve the radiosensi-
tivity of prostate cancer is expected to offer additional normal tissue sparing effects and is 
a promising area of development. Future in-human clinical trials of radiotherapy-specific 
GNPs may shed some light on the impact these particles will have on prostate cancer.
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